Voltage Energy Will Seek New Trial and Review of Verdict in Shoals Patent Dispute

CHAPEL HILL, N.C., Aug. 27, 2026 /PRNewswire/ -- Voltage Energy Group ("Voltage Energy"), a leading solar and clean energy solutions provider founded in North Carolina, today confirmed that it will seek a new trial following the jury's verdict in Voltage's ongoing patent dispute with Shoals Technologies Group, Inc. ("Shoals") in the Middle District of North Carolina.

Voltage Energy strongly disagrees with the jury's verdict and believes the judgment is not supported by legally sufficient evidence or the law. The Company will pursue all available post-trial remedies.

"We are confident in our record for appeal and the Court's prior findings that Shoals violated an agreement prohibiting its counsel's involvement in obtaining these patents," said Li Wang, CEO of Voltage Energy. "Voltage independently developed LYNX in 2021 through its own engineering efforts, three years before the patents asserted by Shoals were issued. Our focus remains on proudly powering the renewable energy industry."

LYNX PLUS, the Company's latest trunk bus solution featuring a 2kV architecture, 0.5–0.8% higher yield, 10–15% material savings, and 34% voltage-drop reduction, remains in full production and continues to ship to customers as scheduled. Building on this foundation, Voltage Energy will proudly unveil new products and technologies at RE+ 2026, taking place November 17–19 at the Las Vegas Convention Center. Customers and partners are invited to explore its latest solutions at Booths N936 and N736. The upcoming opening of Power Ranch in Roxboro, North Carolina, will further mark the Company's next milestone in expansion and innovation roadmap.

About Voltage Energy Group

Founded in 2016, Voltage Energy Group ("Voltage Energy") is a leading global provider of mission-critical power architecture solutions for utility-scale solar, BESS, and data center segments. Headquartered in Chapel Hill, North Carolina, Voltage Energy operates globally with offices in Frankfurt, Germany; Sydney, Australia; and Abu Dhabi, United Arab Emirates.

Rooted in utility-scale solar EBOS, Voltage Energy delivers safe, reliable, and scalable infrastructure solutions that power our partners to move forward with confidence. We strengthen our core business today while building the capabilities required to meet tomorrow's mission-critical energy and infrastructure needs, from BESS and data centers to microgrids and beyond.

Learn more about us at www.voltageenergy.com.

 

 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Voltage Energy Will Seek New Trial and Review of Verdict in Shoals Patent Dispute

BUENOS AIRES, Argentina, Aug. 27, 2026 /PRNewswire/ -- Biosidus, an Argentine biotechnology company with more than four decades of experience in the development and manufacturing of biosimilar medicines, announced that its new bioreactor plant is now operational, increasing the company's biologics production capacity and reinforcing its ability to support potential international demand.

The expansion strengthens Biosidus' industrial platform at a time when healthcare systems are placing increasing emphasis on manufacturing reliability, continuity of treatment and diversified sources of complex biologic medicines.

Developed and manufactured in Argentina, Biosidus' agalsidase beta, its biosimilar enzyme replacement therapy for Fabry disease, represents a significant milestone in the company's biotechnology platform and its growing focus on treatments for rare diseases.

With additional production capacity, Biosidus is strengthening its international supply capabilities and is prepared to engage with partners and health authorities evaluating sustainable and reliable sources of agalsidase beta supply.

"Continuity of treatment is particularly critical for patients living with rare and chronic diseases. Expanding our productive capacity reinforces our commitment to making Biosidus' biotechnology capabilities available to healthcare systems seeking sustainable and reliable access to high-quality biologic medicines," said Mario Koch, Director of Rare Diseases.

After launching agalsidase beta in Argentina in 2025, Biosidus is advancing the international expansion of its program and is available to evaluate extraordinary supply requirements in markets where the applicable regulatory pathways allow it.

The new bioreactor capacity is part of Biosidus' broader strategy of combining scientific capabilities, local manufacturing, industrial investment and international expansion to increase access to complex biologic therapies.

About Biosidus

Biosidus is an Argentine biotechnology company specializing in the development, manufacturing and commercialization of biosimilar medicines. With more than 40 years of experience in biotechnology and a presence in international markets, the company develops and manufactures complex biologic medicines across multiple therapeutic areas.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Biosidus expands biologics manufacturing capacity and strengthens global supply capabilities for agalsidase beta